November 21, 2013
ASCL1 And RET Expression Defines Clinically Relevant Subgroup Of Lung Adenocarcinoma
By Center for Individualized Medicine
A recent publication, featuring the Director of the Biomarker Discovery Program at the Center for Individualized Medicine at Mayo Clinic, George Vasmatzis, examining the role of ASCL1 in the neuroendocrine differentiation of lung adenocarcinoma. The clinical significance of neuroendocrine differentiation in lung adenocarcinoma, and the most appropriate biomarkers for this assessment, has long been debated. In the […]
Tags: ASCL1, biomarker, Biomarker Discovery, Biomarker Discovery Program, cancer, center for individualized medicine, chromogranin, DNA, George Vasmatzis, immunohistochemical, individualized medicine, Lung Cancer